Biostem Technologies Inc
OTC:BSEM

Watchlist Manager
Biostem Technologies Inc Logo
Biostem Technologies Inc
OTC:BSEM
Watchlist
Price: 13.28 USD -1.99% Market Closed
Market Cap: 217m USD
Have any thoughts about
Biostem Technologies Inc?
Write Note

Biostem Technologies Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biostem Technologies Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Biostem Technologies Inc
OTC:BSEM
Gross Profit
$15.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Gross Profit
$60.7B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Gross Profit
$36B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Gross Profit
$42.6B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Gross Profit
$48.4B
CAGR 3-Years
15%
CAGR 5-Years
8%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Gross Profit
$33.1B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
8%
No Stocks Found

Biostem Technologies Inc
Glance View

Market Cap
217m USD
Industry
Pharmaceuticals

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.

BSEM Intrinsic Value
18.02 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Biostem Technologies Inc's Gross Profit?
Gross Profit
15.4m USD

Based on the financial report for Dec 31, 2023, Biostem Technologies Inc's Gross Profit amounts to 15.4m USD.

What is Biostem Technologies Inc's Gross Profit growth rate?
Gross Profit CAGR 1Y
447%

Over the last year, the Gross Profit growth was 447%.

Back to Top